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Abstract
Background: Correct identification of the EGFR c.2369C>T p.(Thr790Met) variant is key to decide on a targeted
therapeutic strategy for patients with acquired EGFR TKI resistance in non-small cell lung cancer. The aim of this
study was to evaluate the correct detection of this variant in 12 tumor tissue specimens tested by 324 laboratories
participating in External Quality Assessment (EQA) schemes.
Methods: Data from EQA schemes were evaluated between 2013 and 2018 from cell lines (6) and resections (6)
containing the EGFR c.2369C>T p.(Thr790Met) mutation. Adequate performance was defined as the percentage of
tests for which an outcome was available and correct. Additional data on the used test method were collected
from the participants. Chi-squared tests on contingency tables and a biserial rank correlation were applied by IBM
SPSS Statistics version 25 (IBM, Armonk, NY, USA).
Results: In 26 of the 1190 tests (2.2%) a technical failure occurred. For the remaining 1164 results, 1008 (86.6%)
were correct, 151 (12.9%) were false-negative and 5 (0.4%) included incorrect mutations. Correct p.(Thr790Met)
detection improved over time and for repeated scheme participations. In-house non-next-generation sequencing
(NGS) techniques performed worse (81.1%, n = 293) compared to non-NGS commercial kits (85.2%, n = 656) and
NGS (97.0%, n = 239). Over time there was an increase in the users of NGS. Resection specimens performed worse
(82.6%, n = 610 tests) compared to cell line material (90.9%, n = 578 tests), except for NGS (96.3%, n = 344 for
resections and 98.6%, n = 312 for cell lines). Samples with multiple mutations were more difficult compared to
samples with the single p.(Thr790Met) variant. A change of the test method was shown beneficial to reduce errors
but introduced additional analysis failures.
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Conclusions: A significant number of laboratories that offer p.(Thr790Met) testing did not detect this relevant
mutation compared to the other EQA participants. However, correct identification of this variant is improving over
time and was higher for NGS users. Revising the methodology might be useful to resolve errors, especially for
resection specimens with low frequency or multiple variants. EQA providers should include challenging resections
in the scheme.
Keywords: Non-small cell lung cancer, External quality assessment, Predictive biomarker, EGFR, c.2369C>T
p.(Thr790Met), Resistance, Osimertinib
Background
The mutational status of the epidermal-growth factor re-
ceptor (EGFR) gene is used as a predictive biomarker for
treatment with targeted therapy in patients with ad-
vanced non-small cell lung cancer (NSCLC) [1–5]. Dem-
onstrating the presence of an activating EGFR mutation
is of crucial importance in considering the use of EGFR-
tyrosine kinase inhibitors (TKIs). These TKIs have
shown improved progression-free survival of patients
with EGFR-mutated NSCLC [1–3], which lead to their
approval by the European Medicines Agency or Food
and Drug Administration [6, 7]. The inhibitors include
reversible first-generation (e.g., gefitinib and erlotinib)
and irreversible second-generation drugs (e.g., afatinib
and dacomitinib).
Despite high initial response rates to first and second
generation EGFR-TKIs, eventually all patients with ad-
vanced NSCLC harbouring an EGFR mutation will pro-
gress on these treatments due to acquired resistance,
with a median progression-free survival of 9.7–13.1
months [8, 9]. The most common mechanism of ac-
quired resistance to first and second generation EGFR-
TKIs is the EGFR c.2369C>T p.(Thr790Met) variant
(often referred to as ‘T790M’), ranging from 51 to 68%
[10–13]. Mechanistically, this base substitution leads to
replacement of a threonine by a methionine resulting in
steric hindrance for binding of these TKIs to the tyro-
sine kinase domain, and decreased TKI effectivity.
Correct, reproducible and timely identification of the
c.2369C>T p.(Thr790Met) variant is important at the
time of relapse for appropriate treatment selection. Pa-
tients with the specific EGFR c.2369C>T p.(Thr790Met)
variant are eligible for treatment with osimertinib, which
also irreversibly targets this variant [14, 15].
In tumor specimens from patients with relapse of
NSCLC after EGFR-TKI treatment, the fraction of mu-
tant alleles with the c.2369C>T p.(Thr790Met) mutation
is nearly always lower than that of the initial EGFR mu-
tation, and an appropriate and sufficiently sensitive
method for EGFR analysis is necessary [16]. A variety of
technologies have been reported to have a range of sen-
sitivities between 62 and 100% [17, 18]. The Therascreen
EGFR RGQ PCR Kit (Qiagen), Cobas EGFR Mutation
Test v2 (Roche) and FoundationOne CDx (Foundation
Medicine) have been approved by the FDA for the detec-
tion of EGFR mutations as companion diagnostics for
tissue specimens [19]. In addition, numerous CE-IVD
tests are becoming available for predictive testing includ-
ing the relevant EGFR mutations.
Laboratories are required to participate in external
quality assessment (EQA) ring studies to regularly dem-
onstrate their performance of predictive testing, and to
compare their test methods according to well-
documented validation or verification procedures [20].
Several European EQA programs have reported on the
performance of predicitive testing for both activating
and resistant clinically relevant EGFR mutations in
tumor tissue samples for individual laboratories and dif-
ferent technologies [21–27].
The aim of this study is to present a longitudinal over-
view of the performance to correctly detect the
c.2369C>T p.(Thr790Met) variant with regard to the test
method, sample type and variant allele frequency (VAF).
For this purpose, we collected results from all samples
with EGFR c.2369C>T p.(Thr790Met) variants from
yearly EQA programs for EGFR analysis in NSCLC be-
tween 2013 and 2018, organized by the European Society
of Pathology (ESP) and the French national Gen&Tiss
consortium [28, 29].
Methods
Formalin-fixed paraffin embedded (FFPE) material was
distributed for further DNA extraction. For the ESP
schemes, tissue slides of both resection specimens and
established cell lines were sent with a thickness of mini-
mum 4–5 μm. Tissue blocks with fixed and embedded
cell lines distributed in 2013 and 2014 were created in-
house (Supplemental Table 1), while the cell line ma-
terial in 2017 was purchased from Horizon Discovery
(Cambridge, UK). In the other years, resection speci-
mens from leftover patient material was collected and
samples were sectioned at a central preparation labora-
tory. For the Gen&Tiss schemes only cell lines were pro-
vided as 1 to 3 FFPE curls (extraction of minimum 400
ng DNA) ordered from Horizon. For all samples, the
presence and VAF of the c.2369C>T p.(Thr790Met)
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variant were validated prior to distribution with next-
generation sequencing (NGS) by an ISO15189-
accredited reference laboratory [20] with experience in
molecular pathology. A detailed overview of the distrib-
uted samples to in total 324 participants between 2013
and 2018 is represented in Table 1. All data used in this
manuscript were retrieved from the EGFR EQA scheme
for NSCLC, between 2013 and 2018 (ESP) and in 2014
and 2016 (Gen&Tiss).
Participants were required to analyze these samples
using their routine procedures within 14 calendar days
and to provide information on the applied methodolo-
gies along with their testing results in an online data-
sheet. Results were assessed by a team of international
experts in molecular pathology using pre-defined and
harmonized scoring criteria [21, 22].
For this study, datasheet entries of EQA cases with the
c.2369C>T p.(Thr790Met) variant were classified into
four categories: (i) technical failures for which no out-
come could be reported because of a test failure, (ii) cor-
rect identification of the c.2369C>T p.(Thr790Met)
variant, (iii) false-negative results, i.e. failure to detect
the c.2369C>T p.(Thr790Met) variant in the sample, (iv)
wrong mutation, in case the mutation was detected but
was incorrectly reported e.g. c.2155G>T p.(Thr790Met)
instead of c.2369C>T p.(Thr790Met). Technical failures
are represented with respect to the total number of tests.
Correct results, false-negatives and wrong mutations
were calculated in relation to the total number of
analyzable tests (total tests minus technical failures). Ad-
equate performance was defined as the percentage of
tests for which an outcome was available and correct
(second category). The EGFR reference sequence applied
Table 1 Overview of the samples distributed during the EQA schemes between 2013 and 2018
Provider Scheme
year
Sample
type
1st EGFR
Variant
VAF
variant 1
(in %)
2nd (and 3rd) EGFR
variant
VAF
variant 2
(in %)
#
participants
#
correct
(%)
# false-
negative
(%)
# wrong
mutation
(%)
#
technical
failure
(%)
ESP 2013 Cell line c.2369C>T
p.(Thr790Met)
25b c.2573T>G
p.(Leu858Arg)
25b 107 65
(70.7)
27 (29.3) 0 (0.0) 15 (14.0)
2014 Cell line c.2369C>T
p.(Thr790Met)
45b c.2573T>G
p.(Leu858Arg)
45b 144 133
(92.4)
10 (6.9) 1 (0.7) 0 (0.0)
Cell line 25b c.2573T>G
p.(Leu858Arg)
25b 144 135
(93.8)
8 (5.6) 1 (0.7) 0 (0.0)
Resection 27 c.2155G>A
p.(Gly719Ser) +
c.2327G>A
p.(Arg776His)
79
76
144 77
(53.5)
66 (45.8) 1 (0.7) 0 (0.0)
2015 Resection c.2369C>T
p.(Thr790Met)
15 c.2573T>G
p.(Leu858Arg)
89 114 92
(84.4)
16 (14.7) 1 (0.9) 5 (4.4)
2016 Resection c.2369C>T
p.(Thr790Met)
19 c.2235_2249del
p.(Glu746_Ala750del)
30 43 42
(97.7)
1 (2.3) 0 (0.0) 0 (0.0)
2017
(Jun.)a
Resection c.2369C>T
p.(Thr790Met)
18 c.2573T>G
p.(Leu858Arg) +
c.2389T>A
p.(Cys797Ser)
35
18
107 87
(81.3)
20 (18.7) 0 (0.0) 0 (0.0)
2017
(Oct.)a
Cell line c.2369C>T
p.(Thr790Met)
20 / / 102 97
(99.0)
1 (1.0) 0 (0.0) 4 (3.9)
2018 Resection c.2369C>T
p.(Thr790Met)
22 c.2573T>G
p.(Leu858Arg)
22 101 101
(100.0)
0 (0.0) 0 (0.0) 0 (0.0)
Resection 43 c.2236_
2248delinsCAAC
p.(E746_A750delinsQP)
80 101 101
(100.0)
0 (0.0) 0 (0.0) 0 (0.0)
Gen&Tiss 2014 Cell line c.2369C>T
p.(Thr790Met)
17 / / 43 39
(92.8)
2 (4.8) 1 (2.4) 1 (2.3)
2016 Cell line c.2369C>T
p.(Thr790Met)
22 c.2573T>G
p.(Leu858Arg)
18 40 39
(100.0)
0 (0.0) 0 (0.0) 1 (2.5)
ESP schemes: all samples were provided on glass slides, Gen&Tiss schemes: cell lines were provided as curls from a cytoblock. For each sample, the percentage of
correct, false-negative results, wrong mutations and technical failures is based on c.2369C>T p.(Thr790Met) detection irrespective of the performance to detect
the additional variants. Technical failures are represented with respect to the total number of tests. Correct results, false-negatives and wrong mutations are
calculated in relation to the total number of analyzable tests (total tests minus technical failures). Refseq EGFR: LRG_304t1 (NM_005228.5). aThe 2017 ESP scheme
was organized in 2 distribution rounds (one in June and one in October). bVariant allele frequency based on the percentage of tumor cells. E.g. cell line of 50%
tumor cells in a wild-type background was considered as a VAF of 25%. Abbreviations: EGFR Epidermal growth factor receptor; ESP European Society of Pathology;
LRG Locus Reference Genomic; VAF variant allele frequency; #, number; /, No second variant and VAF given as sample only contains c.2369C>T p.(Thr790Met)
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throughout this manuscript for description of the vari-
ants is Locus Regerence Genomic (LRG) LRG_304t1
(NM_005228.5).
In total, three samples were excluded from the ana-
lyses: two samples were below the pre-defined VAF cut-
off of 10% (one case with VAF of 1% and one with VAF
6%, respectively), and one sample was excluded because
it was not tested by all participants, yielding a total of
1190 tests.
Statistics were performed using IBM SPSS Statistics
version 25 (IBM, Armonk, NY, USA). Differences in the
percentage of correct entries, false-negatives, wrong mu-
tations or technical failures were calculated by contin-
gency tables (Chi-squared tests or Fisher’s exact tests for
cell counts below 5) for a given category. Significance
levels were set at α = 0.05. For correlation of the VAF
with c.2369C>T p.(Thr790Met) outcome and technical
failures, a ranked biserial correlation was performed with
the occurrence of an error (false-negative or wrong mu-
tation) or technical failure as dichotomous variable
(present versus not present) and VAF as ordinal
variable.
Results
From 2013 to 2018, 12 samples contained c.2369C>T
p.(Thr790Met), on which in total 1190 tests were per-
formed (Table 1). For 26 (2.2%) tests no outcome was
reported because of a technical failure. These 26 failures
were reported by 25 individual laboratories in mostly cell
line cases, with the majority of reasons being that the
DNA concentration was too low for analysis (Supple-
mental Table 2). For the remaining 1164 analyses, 1008
(86.6%) were adequate (outcome available and correct),
151 tests (13.0%) were false-negatives, and for 5 of 1164
results (0.4%) an incorrect mutation was reported by
three different laboratories. Incorrect mutations
Fig. 1 Percentage of analyzable tests with correct c.2369C>T p.(Thr790Met) identification for the different technique types. 2/1190 tests were
excluded as no method information was available, bringing the total analyzed tests on 1188. The two excluded tests were performed in 2013
during a 1st EQA participation, on cell line material with an allele frequency of 25%, and resulted in one correct result and one technical failure.
Correct results are calculated in relation to the total number of analyzable tests (total tests minus technical failures). †The category ‘next-
generation sequencing’ includes both commercial and in-house panels. ‡Non-commercial methods include in-house sequencing methods that
are non-NGS based. ∥The first and second distribution round of the Lung 2017 scheme are counted as two separate participations (4 months
apart). The detailed percentage of correct results, false-negatives, wrong mutations and technical failures is given in Supplemental Table 3.
Abbreviations: EQA, external quality assessment; NGS, next-generation sequencing
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consisted of c.2155G>T p.(Thr790Met) (three times),
c.2174C>T p.(Thr725Met) (once) and c.2369C>T
p.(Tyr790Met) (once).
For the 12 different cases distributed during the dif-
ferent scheme years, the lowest performances were
observed for one cell line in 2013 (70.7%, n = 107)
and one resection specimen in 2014 (53.5%, n = 144)
(Table 1).
Over time, an overall improvement in correct
c.2369C>T p.(Thr790Met) detection was observed, from
70.3% (n = 105 tests) in 2013 to 100.0% (n = 202 tests) in
2018 (Fig. 1, panel a). The three different technique
types also improved over time, being commercial kits
(n = 656), NGS (both commercial and non-commercial
panels) (n = 239), and non-commercial non-NGS se-
quencing methods such as dideoxy or Sanger sequencing
(n = 293) (Fig. 1, panel a).
In addition, the ability to detect the c.2369C>T
p.(Thr790Met) variant was compared to the number of
participations in EQA schemes. In total, 493 tests were
carried out during the laboratories’ first time participa-
tion in EQA, and 77.9% of these tests resulted in a
correct detection of c.2369C>T p.(Thr790Met). Labora-
tories who participated in the EQA scheme for the sixth
or seventh time in a row performed 50 and 14 predictive
tests respectively, and in all of these tests (100.0%) the
c.2369C>T p.(Thr790Met) variant was correctly identi-
fied (Fig. 1, panel b).
Resection specimens performed significantly less
(82.6%, n = 610 tests) compared to cell line material
(90.9%, n = 578 tests). This was especially the case for
non-commercial methods (86.3%, n = 189 for cell lines
versus 71.6%, n = 104 for resections) and commercial kits
(79.5%, n = 344 for resections versus 91.7%, n = 312 for
cellines), but not for NGS (96.3%, n = 162 for resections
and 98.6%, n = 77 for cell lines) (Fig. 1, panel c). Samples
with a VAF between 21 and 30%, performed overall sig-
nificantly worse, while samples with a VAF of more than
40% performed significantly better. For NGS users, the
VAF did not seem to affect the performance as much as
compared to the other technique types (Fig. 1, panel d).
A further biserial rank correlation revealed that false-
negative results and wrong mutations were correlated to
lower VAFs (rrb = 0.058, p = 0.048) in cases for which no
technical failures occurred (n = 1163) (Supplemental
Figure 1, panel A). Considering all tests (n = 1188), no
correlation was observed between the occurrence of
technical failures and the VAF (rrb = − 0.053, p = 0.068)
(Supplemental Figure 1, panel B). The detailed per-
centages of correct results, false-negatives, wrong muta-
tions and technical failures per technique type for the
different EQA scheme years, number of participations,
sample types and VAFs is given in Supplemental
Table 3.
In Fig. 2, the performance of scheme years 2013–2018
were summarized for the most frequently used method-
ologies. The results of all commercial test kits improved
over time. Both Therascreen (EGFR RGQ and pyro) kits
displayed a lower performance in 2017 (both 53.8%) not
observed for the other methods, which was resolved in
2018. In 2014, performance of the Cobas v1 kit was the
lowest, but increased to 100.0% correct identification in
2015, along with the introduction of the v2 kit with a
similarly high performance. Both commercial and non-
commercial NGS methods were introduced between
2014 and 2016 and displayed very good performances
during the first years of use. The most prevalent non-
commercial non-NGS tests also showed an improve-
ment, but were less frequently used in the most recent
scheme years (Fig. 2). The detailed percentages of of cor-
rect results, false-negatives, wrong mutations and tech-
nical failures for the 11 most widely used techniques
depicted in Fig. 2 are given in Supplemental Table 4.
The overall performance of the various methods is
shown in Supplemental Table 5. A wide variety of test
methodologies was used for every technique type, with
varying performances ranging from 46.2 to 100.0%. Be-
tween 2013 (n = 105) and 2018 (n = 202), an increase of
samples tested by NGS was observed from 4.7 to 38.6%,
at the expense of a decrease of non-commercial sequen-
cing methods from 41.9 to 9.9%. The percentage of com-
mercial kits remained stable with 53.3 and 51.5% in the
first and last scheme year, respectively. Note that the
performance of non-commercial in-house sequencing
techniques was significantly lower (81.1%, n = 293 tests,
p < 0.05) compared to commercial kits (85.2%, n = 656
tests) and NGS (97.0%, n = 239 tests).
To evaluate the influence of a change in test method-
ology within laboratories, we evaluated 478 performed
tests. In 303 of the 478 tests (63.4%), the participants
used the same test method as during their previous par-
ticipation. Participants who did not change their
methods and made an error in the EQA scheme, more
frequently reported a false-negative or wrong mutation
in the next scheme (Fig. 3, panel a). In contrast, partici-
pants who reported a technical failure and switched
methods between two EQA schemes, more often were
inable to resolve their technical failure during the next
scheme (Fig. 3, Panel b).
Discussion
We performed a longitudinal analysis of the different
testing methods used by European EQA participants to
detect the c.2369C>T p.(Thr790Met) variant in tissue
samples, and demonstrated a wide variety of methodolo-
gies and percentages of false-negative results.
A lower performance was observed for non-
commercial sequencing techniques compared to
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Fig. 2 Percentage of analyzable tests with correct outcome over time for the 11 most frequently used c.2369C>T p.(Thr790Met) detection
methods. Correct results are calculated in relation to the total number of analyzable tests (total tests minus technical failures). Analysis methods
are represented as reported by the participants in the electronic datasheets. The category ‘next-generation sequencing’ includes both commercial
and in-house panels. Non-commercial methods include in-house sequencing methods that are non-NGS based. The detailed percentage of
correct results, false-negatives, wrong mutations and technical failures for these 11 methods is given in Supplemental Table 4. Abbreviations:
ARMS, Amplification Refractory Mutation System; CAST, Competitive allele-specific TaqMan; EGFR, epidermal growth factor receptor; LNA, locked
nucleic acid; PCR, polymerase chain reaction; PNA, peptide nucleic acid
Fig. 3 Influence of a change in test method on incorrect results (panel a) and technical failures (panel b). Eight hundred one individual
participations were considered of which 323 participations were excluded because they were first participations for which no method
information from the previous participation was available. Incorrect results include participations during which a false-negative or wrong
mutation was reported. The evaluation of the effect of a switch in test method was evaluated on laboratory level for a given participation.
Switching to a new methodology included both a switch of technique type (e.g. from a commercial test kit to NGS) as an upgrade to a higher
version number for a given methodology, given that this might affect the detection limit and variants included in the test. Abbreviations: EQA,
external quality assessment. Chi-squared tests or Fisher’s Exact tests (for cell counts below 5) were used to assess significance
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commercial test kits and NGS. This is not surprising
given that the sensitivity to detect EGFR mutations in
tissue has been reported to be on average 20% for in-
house sequencing techniques (such as Sanger sequen-
cing) compared to 1–5% for commercial kits and NGS
[17, 18]. Results from other EQA schemes also revealed
higher error rates for c.2369C>T p.(Thr790Met) com-
pared to other mutations [21, 22] depending on the used
methodology. In the national Italian EQA scheme, per-
formance was lower for direct sequencing compared to
other techniques, and follow-up confirmed our results
that the switch to more sensitive methods could increase
the percentage of good performers [23, 24]. The individ-
ual studies reported above evaluated the performance to
detect multiple EGFR variants at a certain time-point,
with varying sample numbers and types [17]. Inadequate
method information has often been reported as a study
limitation [25]. This stresses the importance of this study
with longitudinal data on EGFR c.2369C>T p.(Thr790Met)
variant detection. We did not compare the differences
between both EQA providers as only two cell line cases
were included in the study for Gen&Tiss, and additional
data is needed to make solid conclusions in this scheme.
For the Cobas EGFR v1 mutation detection kit, more
false-negative results occurred in the 2014 EQA scheme
(Supplemental Table 4). The majority of errors in 2014
occurred for the resection specimen which contained two
additional variants besides c.2369C>T p.(Thr790Met),
stressing the importance of including such samples in
EQA schemes. The high number of false-negatives were
communicated to the manufacturer, after which the kit
was adapted and no false-negative results occurred in the
next scheme.
In addition, commercial kits in 2017 produced more
false-negative results, caused by the lower performance
of the Therascreen RGQ and Pyro kits (both 46.2%
false-negative results reported on 13 performed tests).
However, the false-negative rate dropped to 0% in 2018.
This was also the case for all other methods in 2018,
and the properties of the distributed samples cannot be
neglected as an influencing factor. Moreover, several
other methods, such as the Cobas EGFR v2 (for plasma
and tissue testing) and NGS-based methods were pre-
dominantly used in later scheme years, and influences of
improved technology and knowledge over time cannot
be discarded.
A switch to more sensitive and high-troughput
techniques has been previously advised [2]. Current
recommendations state that laboratories testing for
c.2369C>T p.(Thr790Met) should deploy assays cap-
able of detecting clinically relevant mutations in as
little as 5% of EGFR alleles, based on the analytical
sensitivity of allele specific real-time polymerase chain
reaction in the clinical trials for third generation TKIs
[2]. This was reflected by our study with an apparent
increase over time from non-commercial testing
methods to more sensitive methods such as NGS.
In NSCLC, the clinical relevance of the EGFR
c.2369C>T p.(Thr790Met) variant at a VAF of 1% in
a tumor-rich tissue sample is still under debate, and
ultimate therapy decisions by the treating physician
need to consider the complete clinical patient context.
For this study, the threshold of variants to be de-
tected was set at 10%, given that this VAF should at
least be detected by the majority of method detection
thresholds in tissue, allowing the comparison with the
earlier scheme years. The possibility of small sub-
clones in routine practice (even as little as 5%), and
the upcoming use of circulating tumor DNA when in-
sufficient tissue or tumor cells are present, stresses
the importance of low VAF detection. This is exem-
plified for the two excluded samples below the 10%
cut-off with false-negative rates of 22.2% (n = 54,
VAF = 6%) and 56.1% (n = 41, VAF = 1%).
In this study, the switch of a laboratory to another
testing method (irrespective of the specific technique
or assay type) had a positive effect on the false-
negative or wrong mutation rates (Fig. 3). These find-
ings emphasize the educational value of EQA partici-
pation and the individual feedback that is provided
afterwards. However, switching of test method re-
sulted in more technical failures. This suggests that
when a new method is adopted, laboratories are still
in a learning phase concerning optimal analysis con-
ditions, and both aspects (errors versus technical fail-
ures) require a different approach. This is in contrast
with previously reported findings, in which changing
the test method for KRAS proto-oncogene GTPase
(KRAS) analysis did not influence the EQA score [27].
One explanation is that the detection of KRAS muta-
tions is restricted to few, well-defined mutations and
single nucleotide polymorfisms in contrast to more
complex EGFR mutations.
One sample with two additional EGFR variants
(c.2155G>A p.(Gly719Ser) and c.2327G>A p.(Arg776His))
displayed the lowest performance, together with a case
with an additional variant c.2573T>G p.(Leu858Arg). For
the latter, the lower performance could be explained by
the fact that this sample was distributed in the first year
(2013) of this EQA scheme and many laboratories were
still experiencing technical failures. This is supported by
the fact that this case contributes to 15 of 26 reported fail-
ures, and that other samples with the same variants dis-
played a better performance in later schemes. For the first
case, the presence of more than one additional mutation
besides c.2369C>T p.(Thr790Met) requires extra caution,
given that primer sequences need to be chosen specifically
enough to prevent binding to nearby regions. This is
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especially the case for c.2369C>T p.(Thr790Met), as this
variant has been reported to occur in less than 5% of treat-
ment naïve primary lung cancers, but in 50% of treated
NSCLC as a concomitant resistance variant in combin-
ation with another sensitizing EGFR variant [15].
Surprisingly, the performance for samples with a VAF
in the lowest category of 11–20% was higher than that
observed at a VAF of 21–30%. This could be explained
by the fact that the category of 21–30% contained the
two most difficult samples mentioned above with a per-
formance score of 53.5% (case with 3 combined EGFR
variants) and 70.7% (only case in the first scheme of
2013). Exclusion of these cases shifts the score to 87.3%
(n = 409) for cases with a VAF of 11–20% and to 93.7%
(n = 285) for cases with a VAF of 21–30%. An additional
correlation indeed confirmed that lower VAFs were sig-
nificantly related to more incorrect detection of
c.2369C>T p.(Thr790Met) (Supplemental Figure 1,
panel a), but not to the number of technical failures
(Supplemetal Figure 1, panel b). However, the number
of technical failures was low (25/1188), and these data
need to be interpreted with caution.
For all categories, cell lines performed better com-
pared to resection specimens, especially for non-
commercial non-NGS methods. In contrast, NGS seems
to perform excellently in both sample types (Supple-
mental Table 3). Cell lines are included by EQA pro-
viders to track performance over time in a repeatable
manner, to perform a technical scheme, or when resec-
tion material is scarce. Our findings now advocate the
use of resection specimens, as cell lines seem to over-
estimate the laboratory’s EQA performance, which could
potentially provide a false sense of security. In addition,
the ISO15189 [20] standard advizes to select an
ISO17043 accredited scheme [29] that distributes mater-
ial reflecting routine practice as close as possible.
The fact that resection specimens performed worse
compared to cell lines and for users of non-commercial
methods compared to commercial methods, could be
explained by tissue heterogeneity, as different technolo-
gies require a different minimal number of neoplastic
cells. Alternatively, the preanalytical factor of delay in
transportation to the pathology department, or in resec-
tion specimen fixation may play a role [30], but is un-
likely to occur with preparation of EQA cell lines.
One limitation of this study might be the omission of
selection and estimation of the neoplastic cell percent-
age, which have been reported to be highly variable [31],
and influence the quantity and quality of extracted DNA
for further analysis. When evaluating the reasons for
technical failures (Supplemental Table 2), the majority
of laboratories mention a too low percentage of neoplas-
tic cells or DNA concentration. However, given the
overall low frequency of technical failures, and the
noticeable difference between methodologies for the
provided cell lines (albeit less as compared to resection
specimens), the analytical method seems to be of great
importance, and EQA scheme participants are advised to
re-check the suitability of their methods if deemed
necessary.
While the percentage of false-negative results was
26% in 2013, no false-negative results were observed in
2018. This improvement might be attributed to the
large increase in NGS users over time, which displayed
an overall higher performance. Therefore, we also eval-
uated the percentage of correctly identified samples in
relation to the number of successive EQA participa-
tions, irrespective of the used methodology. Results
suggested that repeated EQA participation leads to im-
proved performance, without the co-occurrence of a
higher percentage of NGS users (data not shown).
Nevertheless, molecular pathology is a permanently
evolving field, and other factors should be considered,
such as more experience with the distributed EQA ma-
terial, or increased scientific knowledge of the involved
staff by trainings and continuous education.
Despite the high response rates to various first and
second generation EGFR-TKIs, eventually all patients
with advanced NSCLC carrying an EGFR mutation, will
progress due to acquired resistance [8, 9], most often
due to the EGFR p.(Thr790Met) mutation [10–13].
Osimertinib was introduced as a third-generation EGFR-
TKI that selectively and irreversibly targets the EGFR
p.(Thr790Met) mutation. Currently, osimertinib is
approved for treatment of p.(Thr790Met)-positive patients
who have progressed on first or second generation EGFR-
TKIs [14, 15]. However, in 2018 osimertinib was also ap-
proved as first-line therapy for advanced EGFR-mutated
NSCLC regardless of p.(Thr790Met) mutation status [32].
In contract to the other first and second generation
EGFR-TKIs, resistance mechanisms reported for osimerti-
nib are very different and represent only 6–10% secondary
EGFR mutations not including the p.(Thr790Met) muta-
tion [33]. Although the p.(Thr790Met) mutation is not a
major resistance mechanism for patients treated with osi-
mertinib, our findings suggest that also for the detection
of other double EGFR mutations, approved commercial
panels and more sensitive detection methods should be
used.
Conclusions
Our findings illustrate an improvement over time in
the detection of the EGFR c.2369C>T p.(Thr790Met)
mutation mostly in combination with a second activat-
ing EGFR mutation in the same sample, related to an
increased use of NGS. With the lower performance of
non-commercial sequencing methods, it is advised to
switch to approved commercial panels or to use more
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sensitive detection methods for testing of patient resec-
tions. A reconsideration of the test method and re-
peated participation has shown to be favorable in EQA,
especially in resolving already existing errors. Participa-
tion in EQA programs could thus guide laboratories in
identifying method-based shortcomings and in taking
the necessary actions for improvement. EQA providers
are advised to include challenging resection samples
with a low VAF or multiple variants besides cell lines.
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